Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children - PubMed (original) (raw)
Randomized Controlled Trial
. 2011 Dec;30(12):1081-5.
doi: 10.1097/INF.0b013e3182367662.
Affiliations
- PMID: 21983214
- DOI: 10.1097/INF.0b013e3182367662
Randomized Controlled Trial
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children
Steven Black et al. Pediatr Infect Dis J. 2011 Dec.
Erratum in
- Pediatr Infect Dis J. 2012 May;31(5):537
Abstract
Introduction: The hemagglutination inhibition (HI) titer of 1:40, which has been recognized as an immunologic correlate corresponding to a 50% reduction in the risk of contracting influenza, is based on studies in adults. Neither seasonal nor challenge-based correlates have been evaluated in children.
Methods: A total of 4707 influenza vaccine-naive healthy children 6 to 72 months old were randomized in a ratio of 2:2:1 to receive 2 doses of MF-59-adjuvanted influenza vaccine (Novartis Vaccines), trivalent inactivated influenza vaccine subunit (trivalent inactivated influenza vaccine control, GSK), or a saline placebo during the 2007 to 2008 and 2008 to 2009 influenza seasons. The second dose was given 30 days after dose 1. Clinical influenza-like illnesses cases identified by active surveillance were confirmed by reverse transcription polymerase chain reaction testing for influenza. Vaccine immunogenicity 50 days after dose 1 was evaluated in a subset of 777 children.
Results: Immunogenicity and efficacy results for H3N2 were evaluated against the Prentice criteria, which confirmed that the immunogenicity results warranted estimation of an immunologic correlate. We then used the Dunning model fitting the H3N2 antibody titers at day 50 and the influenza cases observed in the immunogenicity subset to estimate a correlate of protection. This analysis revealed that a cutoff HI titer of 1:110 was associated with the conventional 50% clinical protection rate against infection during the entire season, and titers of 1:215, 1:330, and 1:629 predicated protection rates of 70%, 80%, and 90%, respectively. The conventional adult HI titer of 1:40 was only associated with 22% protection.
Conclusions: The use of the 1:40 HI adult correlate of protection is not appropriate when evaluating influenza vaccines in children. Although a cutoff of 1:110 may be used to predict the conventional 50% clinical protection rate, a titer of 1:330 would predict an 80% protective level, which would seem to be more desirable from a public health perspective.
Similar articles
- Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA. Walter EB, et al. Pediatrics. 2006 Sep;118(3):e570-8. doi: 10.1542/peds.2006-0198. Pediatrics. 2006. PMID: 16950948 Clinical Trial. - Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Englund JA, et al. Pediatrics. 2006 Sep;118(3):e579-85. doi: 10.1542/peds.2006-0201. Pediatrics. 2006. PMID: 16950949 Clinical Trial. - Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).
Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y. Skowronski DM, et al. J Infect Dis. 2012 Dec 15;206(12):1852-61. doi: 10.1093/infdis/jis500. Epub 2012 Aug 7. J Infect Dis. 2012. PMID: 22872731 - Influenza vaccines: T-cell responses deserve more attention.
Schotsaert M, Saelens X, Leroux-Roels G. Schotsaert M, et al. Expert Rev Vaccines. 2012 Aug;11(8):949-62. doi: 10.1586/erv.12.71. Expert Rev Vaccines. 2012. PMID: 23002976 Review. - Correlates of vaccine protection from influenza and its complications.
McCullers JA, Huber VC. McCullers JA, et al. Hum Vaccin Immunother. 2012 Jan;8(1):34-44. doi: 10.4161/hv.8.1.18214. Epub 2012 Jan 1. Hum Vaccin Immunother. 2012. PMID: 22252001 Review.
Cited by
- Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing.
Oxford JS. Oxford JS. Br J Clin Pharmacol. 2013 Aug;76(2):210-6. doi: 10.1111/bcp.12146. Br J Clin Pharmacol. 2013. PMID: 23617282 Free PMC article. Review. - Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Khoury DS, et al. Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17. Nat Med. 2021. PMID: 34002089 - Prior vaccinations improve immunogenicity of inactivated influenza vaccine in young children aged 6 months to 3 years: A cohort study.
Ito K, Mugitani A, Irie S, Ishibashi M, Takasaki Y, Shindo S, Yokoyama T, Yamashita Y, Shibao K, Koyanagi H, Fukushima W, Ohfuji S, Maeda A, Kase T, Hirota Y. Ito K, et al. Medicine (Baltimore). 2018 Jul;97(29):e11551. doi: 10.1097/MD.0000000000011551. Medicine (Baltimore). 2018. PMID: 30024549 Free PMC article. Clinical Trial. - Engineered Small-Molecule Control of Influenza A Virus Replication.
Fay EJ, Aron SL, Stone IA, Waring BM, Plemper RK, Langlois RA. Fay EJ, et al. J Virol. 2018 Dec 10;93(1):e01677-18. doi: 10.1128/JVI.01677-18. Print 2019 Jan 1. J Virol. 2018. PMID: 30282710 Free PMC article. - An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets.
Bullard BL, DeBeauchamp J, Pekarek MJ, Petro-Turnquist E, Vogel P, Webby RJ, Weaver EA. Bullard BL, et al. NPJ Vaccines. 2022 Jun 23;7(1):65. doi: 10.1038/s41541-022-00492-y. NPJ Vaccines. 2022. PMID: 35739199 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical